September 27, 2019
Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 2 MoveDMD trial and open-label…